Drug intelligence / Profile preview

AKE-XG

Development stage: Unknown
Lead developer: Akelos
Modality: Small Molecules
Administration: Oral

Overview

AKE-XG is a novel, non-opioid small molecule inhibitor of the Hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1). Developed by Akelos in collaboration with Weill Cornell Medicine, it is designed to treat chronic and neuropathic pain by selectively modulating the excitability of sensory neurons. Unlike traditional opioid therapies, AKE-XG aims to provide effective analgesia without the associated risks of addiction, respiratory depression, or sedation. The technology originated from research at Weill Cornell Medicine and has been supported by multiple NIH grants, including a Fast-Track STTR grant to advance the compound through IND-enabling studies and early clinical development.

Targets

HCN1 (Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1)

Beyond the preview

Go deeper on AKE-XG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKE-XG.

Explore the full profile